Blocking CD200R to improve cancer immunotherapy
CD200R blockade for cancer immunotherapy
This study is looking at a new way to boost cancer treatment by blocking a specific immune receptor called CD200R, which could help your immune system fight tumors better, especially if you have advanced cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10980744 on NIH RePORTER |
What this research studies
This research investigates the potential of blocking the CD200R immune receptor to enhance the effectiveness of cancer immunotherapy. By targeting both T cells and myeloid cells in the tumor microenvironment, the study aims to improve the immune response against tumors. The approach involves using antibody therapeutics to inhibit CD200R, which has shown promise in preclinical models. Patients with advanced cancers may benefit from this innovative treatment strategy as it seeks to optimize immune cell activity against tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced cancers who are seeking new treatment options.
Not a fit: Patients with early-stage cancers or those who do not express CD200+ tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with advanced cancers.
How similar studies have performed: Other research has shown promising results with similar immune checkpoint blockade approaches, indicating potential for success in this area.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Basu, Sujit — Ohio State University
- Study coordinator: Basu, Sujit
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.